Literature DB >> 18427574

Genomic analysis of epithelial ovarian cancer.

John Farley1, Laurent L Ozbun, Michael J Birrer.   

Abstract

Ovarian cancer is a major health problem for women in the United States. Despite evidence of considerable heterogeneity, most cases of ovarian cancer are treated in a similar fashion. The molecular basis for the clinicopathologic characteristics of these tumors remains poorly defined. Whole genome expression profiling is a genomic tool, which can identify dysregulated genes and uncover unique sub-classes of tumors. The application of this technology to ovarian cancer has provided a solid molecular basis for differences in histology and grade of ovarian tumors. Differentially expressed genes identified pathways implicated in cell proliferation, invasion, motility, chromosomal instability, and gene silencing and provided new insights into the origin and potential treatment of these cancers. The added knowledge provided by global gene expression profiling should allow for a more rational treatment of ovarian cancers. These techniques are leading to a paradigm shift from empirical treatment to an individually tailored approach. This review summarizes the new genomic data on epithelial ovarian cancers of different histology and grade and the impact it will have on our understanding and treatment of this disease.

Entities:  

Mesh:

Year:  2008        PMID: 18427574      PMCID: PMC7185304          DOI: 10.1038/cr.2008.52

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  57 in total

Review 1.  Diagnosis and management of epithelial ovarian cancer.

Authors:  Snehal Bhoola; William J Hoskins
Journal:  Obstet Gynecol       Date:  2006-06       Impact factor: 7.661

2.  Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies.

Authors:  H Salazar; A K Godwin; M B Daly; P B Laub; W M Hogan; N Rosenblum; M P Boente; H T Lynch; T C Hamilton
Journal:  J Natl Cancer Inst       Date:  1996-12-18       Impact factor: 13.506

3.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.

Authors:  T R Golub; D K Slonim; P Tamayo; C Huard; M Gaasenbeek; J P Mesirov; H Coller; M L Loh; J R Downing; M A Caligiuri; C D Bloomfield; E S Lander
Journal:  Science       Date:  1999-10-15       Impact factor: 47.728

4.  Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis.

Authors:  D W Cramer; W R Welch
Journal:  J Natl Cancer Inst       Date:  1983-10       Impact factor: 13.506

5.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

6.  Assisted reproduction in patients with early-stage ovarian malignancies.

Authors:  Michael P Steinkampf; Sejal P Dharia; Karen Hammond
Journal:  Fertil Steril       Date:  2003-12       Impact factor: 7.329

7.  In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer.

Authors:  Noelle Gillette Cloven; Ainura Kyshtoobayeva; Robert A Burger; Ing Ru Yu; John P Fruehauf
Journal:  Gynecol Oncol       Date:  2004-01       Impact factor: 5.482

8.  Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Authors:  William E Winter; G Larry Maxwell; Chunqiao Tian; Jay W Carlson; Robert F Ozols; Peter G Rose; Maurie Markman; Deborah K Armstrong; Franco Muggia; William P McGuire
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

9.  Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas.

Authors:  Donald R Schwartz; Sharon L R Kardia; Kerby A Shedden; Rork Kuick; George Michailidis; Jeremy M G Taylor; David E Misek; Rong Wu; Yali Zhai; Danielle M Darrah; Heather Reed; Lora H Ellenson; Thomas J Giordano; Eric R Fearon; Samir M Hanash; Kathleen R Cho
Journal:  Cancer Res       Date:  2002-08-15       Impact factor: 12.701

10.  A distinct molecular profile associated with mucinous epithelial ovarian cancer.

Authors:  V A Heinzelmann-Schwarz; M Gardiner-Garden; S M Henshall; J P Scurry; R A Scolyer; A N Smith; A Bali; P Vanden Bergh; S Baron-Hay; C Scott; D Fink; N F Hacker; R L Sutherland; P M O'Brien
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

View more
  33 in total

1.  ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches.

Authors:  Hua Li; Benjamin G Bitler; Vinod Vathipadiekal; Marie E Maradeo; Michael Slifker; Caretha L Creasy; Peter J Tummino; Paul Cairns; Michael J Birrer; Rugang Zhang
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-05

2.  Influence of CYP3A4 genotypes in the outcome of serous ovarian cancer patients treated with first-line chemotherapy: implication of a CYP3A4 activity profile.

Authors:  Joana Assis; Deolinda Pereira; Mónica Gomes; Dânia Marques; Inês Marques; Augusto Nogueira; Raquel Catarino; Rui Medeiros
Journal:  Int J Clin Exp Med       Date:  2013-08-01

3.  Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence.

Authors:  Benjamin G Bitler; Jasmine P Nicodemus; Hua Li; Qi Cai; Hong Wu; Xiang Hua; Tianyu Li; Michael J Birrer; Andrew K Godwin; Paul Cairns; Rugang Zhang
Journal:  Cancer Res       Date:  2011-08-04       Impact factor: 12.701

4.  Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer.

Authors:  Katherine M Aird; Hua Li; Frances Xin; Panagiotis A Konstantinopoulos; Rugang Zhang
Journal:  Cell Cycle       Date:  2013-10-29       Impact factor: 4.534

Review 5.  Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment.

Authors:  Analisa DiFeo; Goutham Narla; John A Martignetti
Journal:  Mt Sinai J Med       Date:  2009-12

6.  Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients.

Authors:  Magdalena Koczkowska; Natalia Krawczynska; Maciej Stukan; Alina Kuzniacka; Izabela Brozek; Marcin Sniadecki; Jaroslaw Debniak; Dariusz Wydra; Wojciech Biernat; Piotr Kozlowski; Janusz Limon; Bartosz Wasag; Magdalena Ratajska
Journal:  Cancers (Basel)       Date:  2018-11-14       Impact factor: 6.639

7.  Empirical chemosensitivity testing in a spheroid model of ovarian cancer using a microfluidics-based multiplex platform.

Authors:  Tamal Das; Liliane Meunier; Laurent Barbe; Diane Provencher; Olivier Guenat; Thomas Gervais; Anne-Marie Mes-Masson
Journal:  Biomicrofluidics       Date:  2013-01-10       Impact factor: 2.800

8.  Immunohistochemical evidence for the over-expression of Glutathione peroxidase 3 in clear cell type ovarian adenocarcinoma.

Authors:  Hee Joong Lee; Jin Hwan Do; Sumi Bae; Sanghwa Yang; Xianglon Zhang; Ahwon Lee; Young Jin Choi; Dong Choon Park; Woong Shick Ahn
Journal:  Med Oncol       Date:  2010-08-21       Impact factor: 3.064

9.  SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK.

Authors:  Hua Li; Qi Cai; Hong Wu; Vinod Vathipadiekal; Zachary C Dobbin; Tianyu Li; Xiang Hua; Charles N Landen; Michael J Birrer; Margarita Sánchez-Beato; Rugang Zhang
Journal:  Mol Cancer Res       Date:  2012-09-10       Impact factor: 5.852

Review 10.  HMGA2 and high-grade serous ovarian carcinoma.

Authors:  Jingjing Wu; Jian-Jun Wei
Journal:  J Mol Med (Berl)       Date:  2013-05-19       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.